佰維存儲(688525.SH):截至三季度末今年累計在研發投入上已超過1.5億元
格隆匯12月12日丨佰維存儲(688525.SH)近期在接待機構投資者調研時表示,截至三季度末,公司今年累計在研發投入上已超過1.5億元,佔營業收入的比例是7.14%。研發費用主要投入以下方面:在產品應用方向上,主要投入在高端消費電子、工業車規和企業級產品的研發;在技術競爭力提升上,主要投入在存儲器解決方案研發能力的鞏固和增強,並積極投入芯片IC設計、先進封測、芯片測試設備研發等,進一步深化產業鏈佈局優勢;在研發管理層面,公司不斷地提升研發管理以及項目管理的科學化、標準化和IT化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.